Interpace to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright
September 06 2019 - 6:55AM
Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”)
(NASDAQ: IDXG) today announced that the Company will present at the
upcoming 21st Annual Global Investment Conference, sponsored by
H.C. Wainwright & Co., held September 8 - 10, 2019 at the Lotte
New York Palace Hotel. Jack Stover, President and CEO of Interpace,
will provide an overview of the business and will be available to
participate in one-on-one meetings with investors and analysts who
are registered to attend the conference.
Event: H.C.
Wainwright 21st Annual Global Investment
Conference
Presentation: Monday, September
9, 2019 4:15pm - 4:40pm
EST
Location:
Lotte New York Palace Hotel, 4th Floor, Adams
Room
About Interpace Diagnostics Group, Inc.
Interpace is a leader in enabling personalized
medicine, offering specialized services along the therapeutic value
chain from early diagnosis and prognostic planning to targeted
therapeutic applications.
Interpace’s Diagnostic Business is a fully
integrated commercial and bioinformatics business unit that
provides clinically useful molecular diagnostic tests,
bioinformatics and pathology services for evaluating risk of cancer
by leveraging the latest technology in personalized medicine for
improved patient diagnosis and management.
Interpace has four commercialized molecular
tests and one test in a clinical evaluation process (CEP) in its
Diagnostic Business: PancraGEN® for the diagnosis and prognosis of
pancreatic cancer from pancreatic cysts; ThyGeNEXT® for the
diagnosis of thyroid cancer from thyroid nodules utilizing a next
generation sequencing assay; ThyraMIR® for the diagnosis of thyroid
cancer from thyroid nodules utilizing a proprietary gene expression
assay; and RespriDX® that differentiates lung cancer of primary vs.
metastatic origin. In addition, BarreGEN® for Barrett’s Esophagus,
is currently in a clinical evaluation program.
Interpace’s Biopharma Business is a market
leader in providing pharmacogenomics testing, genotyping, and
biorepository services to the pharmaceutical and biotech
industries. The Biopharma Business also advances personalized
medicine by partnering with pharmaceutical, academic, and
technology leaders to effectively integrate pharmacogenomics into
their drug development and clinical trial programs with the goals
of delivering safer, more effective drugs to market more quickly,
and improving patient care.
For more information, please visit Interpace’s website at
www.interpacediagnostics.com.
Contact:Investor RelationsJoe Green, Edison
Groupjgreen@edisongroup.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Sep 2023 to Sep 2024